Clinical Trial

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Study acronym: EAI-714
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-12
notable Primary completion pushed: 2026-06 -> 2027-06 2026-05-12
Trial Details
NCT Number NCT07488117
Lead Sponsor University Hospital, Toulouse
Conditions Autoimmune Encephalitis (AE)
Enrollment 40 participants
Start Date 2026-03-31
Primary Completion 2027-06 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-11